Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Spain's Grifols Acquires Stake in Shanghai RAAS, a Plasma Company, for $1.9 Billion

publication date: Mar 8, 2019

Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Shanghai RAAS, one of China's largest blood plasma companies, for $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in its US subsidiary, Grifols Diagnostic Solutions, for the Shanghai RAAS stake. As part of the agreement, Shanghai RAAS will become exclusive distributor of Grifols' plasma-based and diagnostic products in China, including Grifol's nucleic acid test (NAT) systems used to screen plasma donors for HIV and HCV. More details....

Stock Symbols:(MCE: GRF, MCE: NSDQ: GRFS) (SHZ: 002252)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020